137 related articles for article (PubMed ID: 34953233)
1. A prediction model based on clinical and histological features for predicting recurrence in patients with stage I-II endometrial cancer after surgical treatment.
Song W; Zhao Y
Ann Diagn Pathol; 2022 Feb; 56():151861. PubMed ID: 34953233
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
3. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
4. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
5. The combined ratio of estrogen, progesterone, Ki-67, and P53 to predict the recurrence of endometrial cancer.
Jia M; Jiang P; Huang Z; Hu J; Deng Y; Hu Z
J Surg Oncol; 2020 Dec; 122(8):1808-1814. PubMed ID: 32920817
[TBL] [Abstract][Full Text] [Related]
6. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
8. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.
Yang B; Shan B; Xue X; Wang H; Shan W; Ning C; Zhou Q; Chen X; Luo X
PLoS One; 2016; 11(5):e0155145. PubMed ID: 27163153
[TBL] [Abstract][Full Text] [Related]
9. A Nomogram Model Involving Immunohistochemical Markers for Predicting the Recurrence of Stage I-II Endometrial Cancer.
Jiang P; Jia M; Hu J; Huang Z; Deng Y; Hu Z
Front Oncol; 2020; 10():586081. PubMed ID: 33585205
[TBL] [Abstract][Full Text] [Related]
10. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.
Tomica D; Ramić S; Danolić D; Šušnjar L; Perić-Balja M; Puljiz M
J Obstet Gynaecol; 2018 Jan; 38(1):96-102. PubMed ID: 28764605
[TBL] [Abstract][Full Text] [Related]
11. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
[TBL] [Abstract][Full Text] [Related]
12. Predicting Recurrence in Endometrial Cancer Based on a Combination of Classical Parameters and Immunohistochemical Markers.
Jiang P; Huang J; Deng Y; Hu J; Huang Z; Jia M; Long J; Hu Z
Cancer Manag Res; 2020; 12():7395-7403. PubMed ID: 32922070
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
14. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Fowler JM; Ramirez N; Cohn DE; Kelbick N; Pavelka J; Ben-Shachar I; Morrison C
Am J Obstet Gynecol; 2005 Apr; 192(4):1262-71; discussion 1271-3. PubMed ID: 15846217
[TBL] [Abstract][Full Text] [Related]
15. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A
Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054
[TBL] [Abstract][Full Text] [Related]
16. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
18. Lymphadenectomy in Early-Stage Intermediate-/High-Risk Endometrioid Endometrial Cancer: Clinical Characteristics and Outcomes in an Australian Cohort.
Farrell R; Dixon SC; Carter J; Webb PM
Int J Gynecol Cancer; 2017 Sep; 27(7):1379-1386. PubMed ID: 30814240
[TBL] [Abstract][Full Text] [Related]
19. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
Yu CG; Jiang XY; Li B; Gan L; Huang JF
Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
[TBL] [Abstract][Full Text] [Related]
20. Stromal Clues in Endometrial Carcinoma: Loss of Expression of β-Catenin, Epithelial-Mesenchymal Transition Regulators, and Estrogen-Progesterone Receptor.
Senol S; Sayar I; Ceyran AB; Ibiloglu I; Akalin I; Firat U; Kosemetin D; Engin Zerk P; Aydin A
Int J Gynecol Pathol; 2016 May; 35(3):238-48. PubMed ID: 26367784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
